Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
Open accessThe DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index; 53 of the 149 sources its claims cite were checked for support.
Abstract
Schizophrenia (SCZ) is a psychiatric disorder characterized by a wide range of positive, negative and cognitive symptoms, along with an increased risk of metabolic syndrome and cardiovascular disease that contribute to a 15-20-year reduced life expectancy. Autonomic dysfunction, in the form of increased sympathetic activity and decreased parasympathetic activity, is postulated to be implicated in SCZ and its treatment. The aim of this narrative review is to view SCZ through an autonomic lens and synthesize the evidence relating autonomic dysfunction to different domains of SCZ. Using various methods of assessing autonomic activity, autonomic dysfunction was found to be associated with multiple aspects of SCZ pathophysiology, including symptom severity, cognitive impairment, and the development of cardiometabolic comorbidities, such as metabolic syndrome and high BMI. The strongest association of low heart rate variability was noted among patients on antipsychotic treatment with high-affinity muscarinic antagonism (i.e., clozapine, olanzapine and quetiapine). The review will also suggest ways in which studying autonomic dysfunction can help reduce morbidity and mortality associated with SCZ and its treatment.
Overview
CoChat Summary
## TL;DR
This is a narrative review synthesizing evidence that schizophrenia is associated with autonomic nervous system dysfunction, especially reduced parasympathetic/vagal activity as measured by heart rate variability (HRV). The review argues that this dysfunction is linked to symptom severity, cognitive impairment, and cardiometabolic risk, with stronger HRV reductions often seen in patients taking clozapine, olanzapine, or quetiapine.
## Key findings
- Across studies, patients with schizophrenia had reduced HRV and vagal cardiac control compared with healthy controls; a meta-analytic review of 34 studies found significantly lower HF-HRV and RMSSD in schizophrenia.
- Autonomic dysfunction was associated with symptom severity: higher PANSS scores were negatively correlated with SDNN and RMSSD, and negative symptoms were inversely related to RMSSD and HF while positively associated with LF/HF.
- For cognition, one EDA study found that EDA non-responders had worse performance on verbal comprehension/fluency, memory, perceptual organization, psychomotor function, abstract reasoning, and executive function; another study found no significant difference on MATRICS between responders and non-responders.
- For cardiometabolic outcomes, lower HRV was linked to risk factors such as hypertension, diabetes, and high cholesterol in schizophrenia samples, but one large correlational study found no HRV difference between schizophrenia patients with versus without metabolic syndrome.
## Methods
- Narrative review of the literature on autonomic dysfunction in schizophrenia, with emphasis on HRV and, where relevant, other autonomic measures such as EDA, SAA, catecholamines, and orthostatic cardiovascular responses.
- The review synthesized studies comparing schizophrenia vs healthy controls and, where available, medicated vs unmedicated patients, including evidence on symptom severity, cognition, and cardiometabolic comorbidity.
- Main analysis was qualitative synthesis of prior studies and meta-analytic findings; no new primary sample or original statistical analysis was reported.
## Limitations
- The paper states that the evidence base is limited by the largely cross-sectional nature of the literature, making causality difficult to determine.
- It also notes that whether autonomic dysfunction is intrinsic to schizophrenia or secondary to antipsychotic treatment “has yet to be fully elucidated.”
- Evident from the text: findings across autonomic measures are inconsistent in places (for example, EDA responder/non-responder results and some HRV-symptom correlations), which weakens certainty about some associations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
49 Valid · 1 Not valid · 64 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, the representativeness of SNS output through HRV is somewhat controversial as the LF peak consists of both SNS and PSNS output, making it difficult to separate the dominating system21,25.”
§ Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health > Assessing ANS activity in SCZ
What the sources say
- Not matchedcites [21] Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93, 1043–1065 (1996).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites [25] Thomas, B. L., Claassen, N., Becker, P. & Viljoen, M. Validity of commonly used heart rate variability markers of autonomic nervous system function. Neuropsychobiology 78, 14–26 (2019). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In comparison to non-psychiatric HCs, patients with SCZ exhibit reduced HRV and vagal cardiac control26.”
- Also stated in: § Characterizing autonomic dysfunction in SCZ · plain
“Their findings revealed significantly lower measures of HF-HRV and RMSSD in SCZ, both of which are an estimate of efferent vagal activity of the PSNS.”
§ Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health > Characterizing autonomic dysfunction in SCZ
What the sources say
- Not checked — no full text of the sourcecites [26] Montaquila, J. M., Trachik, B. J. & Bedwell, J. S. Heart rate variability and vagal tone in schizophrenia: a review. J. Psychiatr. Res. 69, 57–66 (2015). source
- Supportedcites [27] Clamor, A., Lincoln, T. M., Thayer, J. F. & Koenig, J. Resting vagal activity in schizophrenia: meta-analysis of heart rate variability as a potential endophenotype. Br. J. Psychiatry 208, 9–16 (2016). source
The Results report significantly lower high-frequency HRV and RMSSD in individuals with schizophrenia than in healthy controls, indicating lower vagal activity. The Discussion describes this as strong evidence of reduced vagal activity across more than a thousand individuals with schizophrenia and an equally large control group. Page numbers were not supplied. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Characterizing autonomic dysfunction in SCZ · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For instance, in two studies that assessed SAA in SCZ, SAA activity levels were significantly higher in a group of SCZ outpatients compared to HC’s14,15.”
§ Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health > Characterizing autonomic dysfunction in SCZ
What the sources say
- Supportedcites [14] Inagaki, T. et al. High salivary alpha-amylase levels in patients with schizophrenia: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 688–691 (2010). source
The Results (p. 10) compare schizophrenia outpatients with healthy controls and report significantly higher salivary alpha-amylase activity in the patient group (p<0.001). The Discussion (p. 12) states the same finding. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [15] Ieda, M. et al. Evaluation of autonomic nervous system by salivary alpha-amylase level and heart rate variability in patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 264, 83–87 (2014). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As mentioned earlier, the meta-analysis did not find any difference in HRV markers of parasympathetic functioning between AP-naïve and medicated patients with SCZ.”
§ Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health > Autonomic dysfunction in SCZ: illness related or AP induced? SCZ is undoubtedly associated with autonomic dysfunction. However, whether it is an intrinsic characteristic of the illness itself or the result of AP treatment has yet to be fully elucidated. This relationship can be teased out by comparing medicated versus unmedicated patients. As mentioned earlier, the meta-analysis did not find any difference in HRV markers of parasympathetic functioning between AP-naïve and medicated patients with SCZ. However, given that both first-generation and second-generation APs modulate serotonergic, dopaminergic, cholinergic and adrenergic neurotransmitter systems, it is likely that APs influence autonomic neurocardiac functioning42 Chang et al.43 conducted a case-control analysis of cardiac autonomic dysfunction in a group of 314 unmedicated patients with acute SCZ and 409 HCs. Frequency domain indices of HRV revealed that unmedicated patients had consistently faster mean heart rates and reduced HF-HRV levels compared to HCs. Similarly, another study examining HRV in acute first-episode drug naïve psychotic patients also found reduced RMSSD, indicating decreased variation in consecutive heartbeats, as well as significantly less HF power during psychosis compared to HCs44. Elsewhere, another study did not show any significant differences in the amount of HRV reduction exhibited by a group of medicated and unmedicated first-episode psychosis patients29. These findings imply that impaired neurocardiac regulation may be related to the illness itself and not secondary to the chronicity of the illness or AP treatment. Low resting-state vagal modulation/parasympathetic activity is also observed in a variety of other psychiatric conditions, such as mood disorders, anxiety disorders and autism spectrum disorder30,45. To this point, many scholars have suggested that reduced HRV may be a transdiagnostic factor associated with baseline psychological discomfort, reduced mental flexibility, stress, and other behavioural factors46,47.
What the sources say
- Partly supportedcites [27] Clamor, A., Lincoln, T. M., Thayer, J. F. & Koenig, J. Resting vagal activity in schizophrenia: meta-analysis of heart rate variability as a potential endophenotype. Br. J. Psychiatry 208, 9–16 (2016). sourceExperimental — accuracy not yet measured
The Meta-regressions and subgroup analyses section reports no significant effect of medication status on high-frequency HRV or RMSSD findings, and the Discussion says reduced vagal activity was found in both medicated and unmedicated groups. But the claim specifies antipsychotic-naïve patients: the Discussion cautions that, except in two first-episode studies, some participants in the unmedicated studies had previously received antipsychotics. The analysis also compared medication-status effects on patient-versus-control differences, not HRV directly between the two patient groups. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Within the SCZ group there were no significant differences in SAA levels between medicated and unmedicated patients14.”
§ Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health > Characterizing autonomic dysfunction in SCZ
What the sources say
- Supportedcites [14] Inagaki, T. et al. High salivary alpha-amylase levels in patients with schizophrenia: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 688–691 (2010). source
The Discussion (p. 12) directly compares five unmedicated patients with 20 sampled from the 49 medicated patients in the schizophrenia group. It reports no statistically significant difference in salivary alpha-amylase levels between them (p=0.06). (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 25 with their cited sources checked
Create a free account to see all 127 claims and every source verdict.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 18
Citations
Cites
Heart Rate Variability: Standards of Measurement, Physiological Interpretation, and Clinical Use
Electrophysiology, T. F. O. T. E. S. O. C. T. N. A. (1996) · Circulation · doi:10.1161/01.cir.93.5.1043 · Cited by 17,159
An overview of heart rate variability metrics and norms
Shaffer, F., & Ginsberg, J. P. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00258 · Cited by 7,185
Porges, S. W. (2007) · Biological Psychology · doi:10.1016/j.biopsycho.2006.06.009 · Cited by 3,415
Thayer, J. F., Åhs, F., Fredrikson, M., Sollers, J. J., & Wager, T. D. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.11.009 · Cited by 3,224
A model of neurovisceral integration in emotion regulation and dysregulation
Thayer, J. F., & Lane, R. D. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00338-4 · Cited by 3,092
Heart rate variability: measurement and clinical utility.
Kleiger, R. E., Stein, P. K., & Bigger, J. T. (2005) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2005.10101.x · Cited by 1,290
Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.04.003 · Cited by 1,284
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
Cited by
The brain–heart axis: integrative cooperation of neural, mechanical and biochemical pathways
Valenza, G., Matić, Z., & Catrambone, V. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01140-3 · Cited by 165
“been observed in acute and chronic stress 15 , neurological injury 19 , epilepsy 20,21 , parkinsonisms 22–24 , Alzheimer disease 25 , psychosomatic disorders 26,27 , schizophrenia 28,29 , anxiety 30 and mood disorders 31–34 .”
Heart Rate Variability in Psychiatric Disorders: A Systematic Review
Ramesh, A., Nayak, T., Beestrum, M., Quer, G., & Pandit, J. A. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s429592 · Cited by 79
“8 HRV remains highly debated in its use as a diagnostic tool due to its variation based on the individual person, as there are differences within patient populations based on sex, age, and BMI; however, with the increasing number of wearable devices with HRV measuring capability, it is imperative…”
Gangopadhyay, A., Ibrahim, R., Theberge, K., May, M. A., & Houseknecht, K. L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042442 · Cited by 55
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
Goh, K. K., Chen, C. Y.-A., Wu, T., Chen, C.-H., & Lu, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137092 · Cited by 49
“Preceding autonomic nervous system dysfunction in persons with metabolic syndrome [306] as well as in those with schizophrenia [307] is another neurobiological factor that is common to schizophrenia and metabolic syndrome.”
BackgroundLonghitano, C., Finlay, S., Peachey, I., Swift, J.-L., Fayet‐Moore, F., Bartle, T., Vos, G., Rudd, D., Shareef, O., Gordon, S., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1444483 · Cited by 42
Metadata
- Authors
- Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Corresponding author
- Agarwal, Sri Mahavir
- ORCID
- Venue
- npj Schizophrenia
- Published
- 2021-04-26
- Volume
- 7
- Issue
- 1
- Pages
- 22-22
- ISSN
- 2334-265X (ISSN-L)
- PMC
- PMC8076312
- OpenAlex
- W3157256311
- Cited by
- 98
- References
- 112
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 20 · 2023: 12 · 2022: 18 · 2021: 6
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Schizophrenia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Physicians' Services Incorporated Foundation
- University of Toronto
- Department of Psychiatry, University of Toronto (PJT-153262)
- Canadian Institutes of Health Research (153262_1)
- Banting and Best Diabetes Centre, University of Toronto (PJT-153262)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- autonomic dysfunction, cognitive impairment, metabolic syndrome, cardiometabolic comorbidities, heart rate variability, sympathetic activity, parasympathetic activity, antipsychotic drugs, muscarinic antagonism, clozapine, olanzapine, quetiapine, body mass index, cardiovascular disease, life expectancy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. https://app.cochat.ai/papers/10.1038/s41537-021-00151-6
- The paper
- Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M. (2021). Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. npj Schizophrenia. https://doi.org/10.1038/s41537-021-00151-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.